December 22, 2014
Patients with hepatitis B virus infection who underwent monotherapy with pegylated interferon had decreased hepatitis B surface antigen expression and an increased rate of sustained response, according to study data.
Researchers enrolled 119 patients from two previously randomized clinical trials to determine the safety and efficacy of PEG-IFN therapy in patients positive and negative for hepatitis B e antigen. All of the patients were previously treated with PEG-IFN monotherapy with a posttreatment follow-up of 6 months. Fifty-two patients were HBeAg-positive and 67 were HBeAg-negative.